Indium (111In) biciromab
|Target||Fibrin II, beta chain|
|(what is this?)|
Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood. It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism, but was withdrawn during clinical trials.
- King, David J.; John R. Adair (1999). "Recombinant antibodies for the diagnosis and therapy of human disease". Current Opinion in Drug Discovery & Development. 2 (2): 112. ISSN 1367-6733.
- Answers.com: Centocor Ortho Biotech Products, L.P.
- DiagnosticImaging.com: Centocor withdraws imaging agent applications
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|